To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
VC-backed Verve Therapeutics goes public
Verve Therapeutics, a biotech company focused on treating cardiovascular disease, has raised $266.7 million for its IPO after pricing its over 14 million shares at $19 per share.
